First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA SEE THE DATA

Plaque Psoriasis
3 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. Read more
*Estimates of patients treated reflect global data since launch (Apr 2014-Aug 2022; US=approximately 60% of data). Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
FDA, U.S. Food and Drug Administration; PsA, psoriatic arthritis; TB, tuberculosis.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Otezla® (apremilast) FDA approval letter. March 21, 2014.
Statistically significant treatment difference ‡,§: (95% CI) = 31% (18%, 43%)
*Complete oral ulcer response is defined as oral ulcer–free. †Patients for whom data are not available to determine response status are considered nonresponders.
‡Adjusted difference in proportions is the weighted average of the treatment differences across the 4 strata of combined sex and region factors with the Cochran-Mantel-Haenszel weights. §Otezla vs placebo. 2
Patients initiated on placebo were switched to Otezla 30 mg BID at week 12
All patients in both arms received Otezla 30 mg BID at week 12 through week 64
Patients entered a 4-week, post-treatment observational follow-up period following discontinuation of Otezla at or before week 64
Post-hoc analysis is exploratory and has not been adjusted for multiple comparisons. No conclusions of statistical or clinical significance can be drawn.
**Patients entered a 4-week post-treatment observational follow-up phase following discontinuation of Otezla at or before week 64.
BID, twice daily; CI, confidence interval; ITT, intent to treat.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for the full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for
phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Hatemi G, Mahr A, Ishigatsubo Y, et al. N Engl J Med. 2019;381(20):1918-1928.